Form 4: BioMarin Director Maykin Ho Receives Equity Grant

BioMarin Pharmaceutical Inc. director Maykin Ho was granted 7,490 restricted stock units as part of an equity compensation arrangement.

Summary

• Director Maykin Ho acquired 7,490 shares of BioMarin Pharmaceutical Inc. (BMRN) common stock via restricted stock units.
• The transaction occurred on June 2, 2026.
• Following this transaction, the reporting person holds a total of 35,500 shares of common stock.
• The shares were granted at a price of $0, representing standard equity compensation for board service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents standard director compensation rather than a market-driven trade.

Positives

• Alignment of director interests with shareholders through increased equity ownership.

Negatives

• None identified.

Risks

• Standard market risks associated with holding equity in a pharmaceutical company.

Future Outlook

Not applicable as this is a routine disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices in the biotechnology sector to ensure long-term alignment with shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units to non-employee directors is consistent with compensation practices at peer mid-to-large cap pharmaceutical companies.

Stakeholder Impact

• Minimal impact on shareholders; reflects standard board compensation structure.

Next Steps

• No further actions required by the reporting person regarding this specific transaction.

Key Dates

Keywords

BioMarin, BMRN, Insider Trading, Form 4, Equity Compensation, Director Ownership